M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
Address: Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA,United Kingdom
Tel: +44 (0) 1865 783 000
Web: http://www.oxfordbiomedica.co.uk/
Oxford BioMedica has established a platform of technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. Through in-house and collaborative development, the Company has a broad pipeline of gene-based product candidates for the treatment of age-related or inherited neurodegenerative and ocular diseases. In addition, Oxford BioMedica and its collaborators are developing novel targeted therapies and therapeutic vaccines to treat multiple types of cancer.
Oxford BioMedica’s two lead programmes are a gene therapy for Parkinson’s disease (ProSavin®) in Phase I/II development and a therapeutic cancer vaccine (TroVax®) in Phase II development.
The other products include RetinoStat®, StarGen™, UshStat™, EncorStat™, MoNuDin®, Hi-8® MEL, MetXia®, EndoAngio-GT and Targeted Antibody Therapy.
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…